FDA Accepts NDA for Lecanemab Subcutaneous Autoinjector, RAP-219 Shows Promise in Early Trials, Blarcamesine Treatment ...
WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I'm Marco Meglio. According to a new announcement, the FDA has accepted Eisai’s biologics license application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector …